Preview

Медицинский Совет

Расширенный поиск

ПРЕОДОЛЕВАЕМ БАРЬЕРЫ В НАЗНАЧЕНИИ ГОРМОНАЛЬНОЙ КОНТРАЦЕПЦИИ (КЛИНИЧЕСКАЯ ЛЕКЦИЯ)

https://doi.org/10.21518/2079-701X-2016-12-56-60

Полный текст:

Аннотация

В статье представлены сведения о составе, механизме действия, побочных эффектах и дополнительных неконтрацептивных возможностях современных пероральных гормональных контрацептивов (ГК). Обоснован универсальный подход к назначению ГК с позиции общности их контрацептивного действия, профиля безопасности и частоты побочных эффектов. Представлены примеры использования ГК с учетом индивидуальных особенностей и желаний женщины на основании их дополнительных неконтрацептивных свойств.

Об авторах

О. А. Пустотина
Российский университет дружбы народов, Москва
Россия

Доктор медицинских наук,  профессор



Э. Р. Герейбекова
Российский университет дружбы народов, Москва
Россия


Список литературы

1. ВОРЗ Репродуктивное здоровье населения России 2011, резюме отчета. Росстат, Минздрав РФ, ЮНФПА, 2012. http//www.gks.ru/free_doc/ new_site/population/zdrav/zdravo-2011.pdf. / WHO Reproductive Health of Russian Population 2011, report abstract. Rosstat, Ministry of health of RF, United Nations Fund for Population Activities, 2012. http//www.gks.ru/free_doc/new_site/population/zdrav/zdravo-2011.pdf.

2. WHO. Medical eligibility criteria for contraceptive use. Fifth edition, 2015. 125 р.

3. Speroff L and Fritz MA. Regulation of the Menstrual Cycle. In: Clinical Gynecologic Endocrinology and Infertility, 2005: 187-231.

4. Grow DR. Metabolism of endogenous and exogenous reproductive hormones. Obstet Gynecol Clin North Am, 2002, 29: 425-436.

5. Collaborative group. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endome-trial cancer from 36 epidemiological studies. The Lancet Oncology, 2015, 16(9): 1061-1070.

6. Collaborative group. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. The Lancet, 2008, 371(9605): 303-314.

7. Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: improving the risk to benefit ratio. Contraception, 2011, 84: 19-34.

8. Hannaford PC, Iversen L, Macfarlane TV et al. Mortality among contraceptive pill users: Cohort evidence from RoyalCollege of General Practitioners'Oral Contraception Study. BMJ, 2010, 340: 927. doi: 10.1136/bmj.c927.

9. Schindler AE, Campagnoli C, Druckmann R et al. Classification and phar macology of proges-tins. Maturitas, 2008, 61: 171-180.

10. Schindler AE. Non-contraceptive benefits of hormonal contraception. Minerva Ginecol, 2010, 62: 319-329.

11. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev, 2012, 2: CD006586.

12. Caprio M. Antiadipogenic effects of the drospirenone: potential implications for the treatment of metabolic syndrome. Endocr, 2011.

13. Nevatte T, O'Brien PM, Backstrom T et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health, 2013, 16(4): 279-91.

14. Руководство по контрацепции. Под ред. проф. В.Н. Прилепской. 3-е изд., перераб. и доп. М.: МЕДпресс-информ, 2014. 464 с. / Guidance on contraception. Ed. by Prof. V.N. Prilepskaya, Ed. 3, revised and supplemented. M.: MEDpress-inform, 2014, 464 p.

15. Прилепская В.Н., Межевитинова Е.А., Сасунова Р.А., и соавт. Результаты клинического применения препарата, содержащего дроспиренон, у женщин с тяжелой формой предменструального синдрома. Акуш и гинекол., 2012, 2: 5-11. / Prilepskaya V.N., Mezhevitinova E.A., Sasunova R.A. et al. Results of clinical application of the drospirenon-containing drug in women with a grave form of premenstrual syndrome. Akush I Ginekol., 2012, 2: 5-11.

16. Christin-Maitre S, Serfaty D, Chabbert-Buffet N, et al. Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17p-estradiol (NOMAC/E2): a double-blind, randomized study. Hum Reprod, 2011, 26: 1338-1347.

17. Epperson CN. Premenstrual dysphoric disorder and the brain. American Journal of Psychiatry. 2013,170:248-252.

18. Pasquali R, Gambineri A. Treatment of hirsutism in the polycistic ovary syndrome. Eur J Endocrinol, 2014, 170, 75-90.

19. Heit J, Kobbervig C, James A et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study. Ann Intern Med, 2005, 143(10): 697.

20. Dinger J, Heinemann L, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contrac, 2007, 75(5): 344-354.

21. Roach REJ, Helmerhorst FM, Lijfering WM et al. The risk of heart attack and stroke in women using birth control pills. Cochrane Library, 2015: CD011054.

22. Dinger J, Mhoner S, Heinemann K. Cardiovascular risks associated with the use of drospire-none-containing combined oral contraceptives. Contraception, 2016, 93(5): 378-385.

23. WHO/RHR. Family Planning: A Global Handbook for Providers. Baltimore and Geneva: CCP and WHO, 2011.

24. Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev, 2010, 1: CD007541.

25. Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75 mcg desogestrel-only contraceptive pill (Cerazette®) after scheduled 12-hour delays in tablet-intake. Contraception, 2005, 71: 8-13.

26. Ahrendt HJ, Karckt U, Pichl T et al. The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results from two studies on oestrogen. Eur J Contracept Reprod Health Care, 2007, 12(4): 354-61.

27. Nappi RE, Merki-Feld GS, Terreno E. Hormonal contraception in women with migraine: is pro-gestogen-only contraception a better choice? J Headache Pain, 2013, 14(1): 66.

28. Mantha S, Karp R, Raghavan V et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ, 2012, 345: e4944.

29. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ, 2009, 339: b2890.

30. WHO Task force on oral contraceptives. Effects of hormonal contraceptives on breast milk composition and infant growth. Stud. Fam. Plann., 1988, 19: 361-369.

31. Truitt ST, Fraser AB, Grimes DA et al. Combined hormonal versus nonhormonal versus proges-tin-only contraception in lactation. Cochrane Data-base Syst Rev, 2003, 2: CD003988.

32. Bjarnadottir RI, Gottfredsdottir Н, Sigurdardottir К et al. Comparative study of the effects of a pro-gestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women. Br J Obstet. Gynaecol, 2001, 108: 1174-80.

33. Knight J, Pyper C. Postnatal contraception: what are the choices? Nursing in Practice, 2002, May: 23-5.

34. Charnock-Jones DS, Macpherson AM, Archer DF et al. The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endo-metrium. Hum Reprod, 2000, 15: 85-95.

35. Dhont M. History of oral contraception. Eur J Contracept Reprod Health Care, 2010, 15(S2): 12-18.

36. Alkema L, Kantorova V, Menozzi C, Biddlecom A. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planing between 1990 and 2015: a systematic and comprehensive analysis. Lancet, 2013, 381: 1642.

37. Lopez LM, Steiner M, Grimes DA et al. Strategies for communicating contraceptive effectiveness. Cochrane Database Syst Rev, 2013, 4: CD006964.


Просмотров: 179


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)